Sema4 Holdings Corp - Ordinary Shares - Class A Stock News

GAITHERSBURG, Md.--(BUSINESS WIRE)--The GUARDIAN study has been recognized as one of the most impactful scientific contributions published across all JAMA journals this year.

The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull market.

GeneDX provides an artificial intelligence-powered genetic testing platform. CEO Katherine Stueland sold about $300,000 worth of shares on Oct. 29.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK , Nov. 30, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders.

Sold 69,858 shares, reducing stake value by about $6.45 million Post-trade stake in GeneDx Holdings Corp: zero shares, $0 value The position previously comprised 1.9% of the fund's AUM as of the prior quarter

Sold 69,858 shares, reducing stake value by about $6.45 million Post-trade stake in GeneDx Holdings Corp: zero shares, $0 value The position previously comprised 1.9% of the fund's AUM as of the prior quarter

Added 120,000 shares of GeneDx Holdings, an increase valued at ~$12.93 million Post-trade stake: 120,000 shares worth $12.93 million as of September 30, 2025 GeneDx Holdings is not among Telemark Asset Management's top five positions by size

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting.